DUBLIN, Jan. 4, 2023 /PRNewswire/ — The “Type 2 Diabetes Treatment: Global Market Outlook” report has been added to ResearchAndMarkets.com’s offering.
The market has been segmented based on route of administration, therapy type and region. The report provides an overview of the global type 2 diabetes treatment market and analyses market trends.
Using 2021 as the base year, it provides estimated market data for the forecast period of 2022 to 2027. Revenue forecasts for this period are segmented based on route of administration, therapy type and geography. Market values have been estimated based on the total revenue of type 2 diabetes therapies providers.
The report covers the market for type 2 diabetes treatment with regard to the therapy type across different regions. It also highlights major trends and challenges that affect the market and the vendor landscape. It estimates the global market for type 2 diabetes treatment in 2021, and then provides projections for the expected market size through 2027.
The scope of the study includes the various types of medicines involved in type 2 diabetes treatment and management. Blood glucose monitoring, diagnostic systems and devices, and insulin-delivery devices used in the treatment of type 2 diabetes, however, have been excluded from this study.
Report Includes
A comprehensive overview of the global market for the treatment of type 2 diabetes
Analyses of the global and regional market trends, with historic revenue data from 2019 to 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027
Understanding of the current and future market potential for this innovation driven market, and areas of focus to forecast the market into various segments and sub-segments
Discussion of the industry growth driving factors and challenges that will shape the market for type 2 diabetes treatment as the basis for projecting demand in the next few years (2022-2027)
Estimation of the actual market size and revenue forecast for global type 2 diabetes treatment market, and corresponding market share analysis by therapy type, route of administration, end user, and region
Holistic review of the COVID-19 pandemic implications on the global market for treatment of type 2 diabetes
Review of the patent grants and patent applications on type 2 diabetes treatment solutions and related technologies
Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
Key Topics Covered:
Chapter 1 Market Outlook
1.1 Market Snapshot
Chapter 2 Executive Summary
Chapter 3 Market Overview
3.1 Type 2 Diabetes Overview
3.1.1 What is Type 2 Diabetes?
3.1.2 Prevalence and Epidemiology of Type 2 Diabetes
3.1.3 Diagnosing Type 2 Diabetes
3.1.4 Treatment for Type 2 Diabetes
3.2 Market Drivers
3.2.1 Rising Prevalence of Diabetes
3.2.2 Next Generation of Type 2 Diabetes Treatment
3.2.3 High Unmet Need
3.2.4 Premium Pricing
3.2.5 Collaborations and Licensing Agreements
3.3 Market Challenge
3.3.1 Loss of Exclusivity, Genericization and Pricing Pressure
3.3.2 Evolving Regulatory Scenario
3.4 Impact of Covid-19
Chapter 4 Emerging Trends and Opportunities
4.1 Patient Outcomes Beyond Glucose Control
4.2 Diabetes Technology With Digital Health
4.3 Growing Trend Toward Oral Antidiabetics
4.4 Growing Focus on Accessibility and Affordability of Medicine
Chapter 5 Market Breakdown by Route of Administration and Therapy Type
5.1 Type 2 Diabetes Treatment Market by Route of Administration
5.1.1 Market Size and Forecast
5.2 Injectable Therapies Market by Type
5.2.1 Insulin Therapy
5.2.2 Glucagon-Like Peptide 1 Therapy
5.2.3 Market Size and Forecast
5.3 Oral Medications Market by Drug Class
5.3.1 Dipeptidyl Peptidase-4 Inhibitors
5.3.2 Sodium-Glucose Cotransporter-2 Inhibitors
5.3.3 Glucagon-Like Peptide 1 Receptor Agonists
5.3.4 Other Oral Antidiabetic Medications
5.3.5 Market Size and Forecast
5.4 Type 2 Diabetes Treatment Market by Therapy Type
5.4.1 Market Size and Forecast
5.5 Insulin Therapy Market by Insulin Type
5.5.1 Market Size and Forecast
5.6 Non-Insulin Therapies Market by Drug Type
5.6.1 Market Size and Forecast
Chapter 6 Market Breakdown by Region
6.1 Type 2 Diabetes Treatment Market Size by Region
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Rest of the World
Chapter 7 Competitive Landscape
7.1 Global Market Shares of Leading Companies
7.2 Recent Key Developments
7.3 Blockbuster Diabetes Drug and Therapy Revenue
7.4 Facing the Patent Cliff
Chapter 8 Company Profiles
Astrazeneca plc
Biocon
Boehringer Ingelheim International GmbH
Eli Lilly and Co.
Janssen Pharmaceuticals Inc. (Johnson & Johnson)
Merck & Co. Inc.
Novartis AG
Novo Nordisk A/S
Sanofi
Chapter 9 Project Scope and Methodology
For more information about this report visit https://www.researchandmarkets.com/r/f431dy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-type-2-diabetes-treatment-market-outlook-report-2022-2023–2027-patent-cliff-oral-antidiabetics-and-growing-focus-on-accessibility-and-affordability-of-medicine-bolsters-growth-301713486.html
SOURCE Research and Markets
As 2023 starts gearing up for the long haul, Wall Street is still taking a bearish view of the markets. We’re still dealing with the same headwinds, a combination of stubbornly high inflation, rapidly rising interest rates, gloomy economic indicators, the continuing war in Ukraine, uncertainty over China’s lockdown policies, a supply chain that is only slowly unsnarling itself… the list can go on. But despite the grim outlook right now, there are still some signals that give reasons for longer-t
Buffett's company, Berkshire Hathaway, is much more invested in the tech sector than it used to be.
After releasing topline late-stage clinical trial data on its drugs effect on a set of precancerous conditions, a longtime Bay Area biotech said it plans to raise $175 million through a stock sale. Geron Corp. (NASDAQ: GERN) said early Wednesday that its drug, called imetelstat, met the primary efficacy goal in a Phase III study in certain patients with myelodysplastic syndromes, or MDS. The company said it will submit the data to the Food and Drug Administration as it asks the agency this year to approve the drug.
Among Meta Platforms (formerly Facebook), Amazon, Apple, Netflix, and Alphabet (formerly Google), there are two rock-solid buys and one well-known industry leader to avoid.
A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted.
The bear run of 2022 was brutal on stock investors, in fact, it was the worst market year since the Great Recession of 2008. But – some of the Street’s strategists are predicting that this year has a recovery, or at least a partial rebound, in store. Even though the S&P 500 lost nearly 20% last year, inflation is still running at more than 7% annualized, and the Federal Reserve has bumped interest rates up to 4.25% in response, John Stoltzfus, Oppenheimer Asset Management chief investment strate
The current rate is good, but if you hold off until just before the next change, it could be even better.
The On-Balance-Volume (OBV) line shows some slight improvement from late September. The Moving Average Convergence Divergence (MACD) oscillator is bullish. The weekly OBV line has stayed steady but the MACD oscillator is now above the zero line and bullish.
What to watch in markets on Thursday, January 5, 2023.
The big market headline last year has been the steady fall in stocks. The S&P 500 tumbled 19% for 2022, and the NASDAQ has fallen a disastrous 33%. And while recent data shows that there may be some hope on the inflation front, there may still be storm clouds massing for this year’s stock market. In times like these, it’s natural to turn to the high-yield dividend payers. These stocks offer the twin advantages of a steady income stream through regular, reliable dividend payments – and dividend y
After a tough 2022, this could be the year that fixed income is a better bet than stocks. Here’s what some of the experts recommend buying now.
Shares of telecom giant Verizon (NYSE: VZ) were rising today, up as much as 3.3% before settling into a 2.5% gain on the day. While the markets were broadly positive, Verizon's outsized gains were likely due to its CEO's appearance at a Citigroup telecom and technology conference today, during which CEO Hans Vestberg had positive things to say about the recently concluded fourth quarter. Without giving too many details, Vestberg stated that the company saw positive net additions in the fourth quarter, and that store traffic had increased compared with prior periods.
As FTX collapsed in November, crypto bank Silvergate experienced a bank run. Deposits plunged by $8.1 billion in the fourth quarter.
At the same time, concerns grew about dependence on China and Taiwan. As a result, policymakers passed the $53 billion Chips and Science Act. With globalization’s golden age potentially in the rearview, we are seeing a rise in nationalistic policies.
A longtime equity analyst provides some perspective.
No Fed officials thought it’d be appropriate to begin cutting rates in 2023, as members thought that that price pressures could prove to be more persistent than anticipated with the job market remaining so strong for longer than anticipated, according to internal discussions of Fed officials at their policy meeting three weeks ago.
Yahoo Finance Live breaks down analyst concerns in Microsoft's Azure cloud unit, also commenting on the tech company's partnership with ChatGPT.
Although last year was challenging for most of Wall Street, it was an especially difficult year for growth stocks. When the curtain closed on 2022, both the growth-dependent Nasdaq Composite and the Nasdaq 100 — an index comprised of the 100 largest nonfinancial companies listed on the Nasdaq exchange — lost 33% of their value. The thumping that Nasdaq 100 stocks took last year can be a blessing in disguise for opportunistic growth seekers looking to pounce.
Microsoft stock is down more than 5% following a downgrade from UBS. Is it a buying opportunity or are still lower prices in store?
Livent (LTHM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.